Deep Brain Stimulators (DBS) Market By Product Type (Devices {Single-lead DBS systems, Dual-lead DBS systems}, Accessories {Batteries, Connectors, Leads}), By Application (Parkinson’s Disease, Epilepsy, Essential Tremor, Dystonia, Obsessive-Compulsive Disorder (OCD), Other Neurological Disorders), By Technology (Conventional DBS Systems, Responsive DBS Systems), By End-User (Hospitals, Neurology Clinics, Ambulatory Surgical Centers, Research Institutions), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Deep Brain Stimulators (DBS) market accounted for USD 1.83 Billion in 2024 and is expected to reach USD 4.35 Billion by 2035, growing at a CAGR of around 8.2% between 2025 and 2035. Deep brain stimulators (DBS) are implantable devices that insert electrodes and provide electrical impulses to brain circuits to treat neurological illnesses. These implants include a pulse generator, electrodes, and a wire through which this machine regulates abnormal brain activity. Mainly employed in Parkinson’s disease, essential tremor, and dystonia, the treatment could be the best option where drugs are insufficient. The DBS market is growing because of technological advancements and the augmentation of neurological disorders, and people's understanding of treatment options for these diseases makes it significant in neuromodulation therapy.

Report Scope:

Market Dynamics

Increasing acceptance of neuromodulation therapies

Various reasons favor the acceptance of neuromodulation therapy, especially the DBS. Diseases such as Parkinson’s disease and epilepsy increase each year, and patients require effective treatment. DBS's relative safety has increased as technology has advanced, showing its benefits for both patients and doctors. Additional studies have also shown the effectiveness of stem cell treatment, and patients’ feedback helped make it popular among doctors. Cohort studies of DBS published by the National Institutes of Health (NIH) found that the quality of life of patients with movement disorders improves when treated with DBS, and about 70 percent of patients benefit from the treatment. The progress in the design of more advanced, consumer-oriented devices has also become the driving force for embracing the technology as they enable further customization of the treatment process. These factors point to solid ground for neuromodulation therapies in modern medicine, which seems to be gradually turning to new techniques in treating chronic neurologic disorders.

Rising prevalence of neurological disorders

People are becoming more sensitive to neurological disorders such as Parkinson's disease, epilepsy, and dystonia, which is driving the demand for deep brain stimulators (DBS). As the world's population lives longer, the prevalence of the diseases will increase the demand for effective interventions. The market is driven by alternatives for DBS devices with compact sizes, extended battery life, and the proliferation of wireless possibilities. Furthermore, neuromodulation therapy use is increasing as treatment information becomes more widely available and patients and clinicians accept it more readily. The World Health Organization estimates that 50 million people will have an epileptic seizure in a single day. Epilepsy is a chronic disorder that requires novel treatments, such as DBS. It reveals possibilities to expand the market and develop technologies.

High costs associated with DBS procedures

The Deep Brain Stimulation (DBS) market has several challenges due to the expensive procedures involved. The expenses include the DBS devices, the surgical costs, hospitalization, and aftercare, so DBS is unaffordable to most patients. Furthermore, problems with insurance payments from insurers can lead to inefficiencies for everyone concerned, including healthcare providers and patients. This complexity, particularly the demand to use the efforts of skilled specialists, results in expensive expenses. However, question marks about the long-term efficacy and risks of the method discourage patients and doctors from the use of DBS in practice. The lack of information regarding DBS among patients and clinicians can limit its advancement. Strict rules for approving new devices and lengthy appraisal processes stifle market development and product innovation, harming the overall DBS industry.

Integration with digital health technologies and telemedicine

The use of digital health technologies and the increased role of telemedicine are considered the strong driving factors for the Deep Brain Stimulator (DBS) market. This article explains how using remote monitoring and data analysis allows for the improvement of patient care for such illnesses as Parkinson’s and dystonia. Telemedicine ensures that stimulation parameters are changed in real-time, eliminating the need for multiple face-to-face sessions. Patient engagement must include the use of mobile applications to track symptoms and side effects so that interventions can begin as soon as possible. Integrating DBS with digital health technologies enhances patient happiness and clinical practice, potentially increasing DBS market strategies.

Strategic collaborations and partnerships in research

The opportunities for strategic research collaborations improve as the demand for deep brain stimulators (DBS) and other neuromodulation therapies rises. Collaboration among device makers, academic institutions, and healthcare practitioners advances the development of DBS while boosting its safety and efficacy. These partnerships can help clinical researchers combine resources and capabilities to gain regulatory approval and increase market penetration in a shorter period. Moreover, DBS systems are used to develop patient-specific treatment programs using machine learning and artificial intelligence. Owing to the growing number of neurological disorders, partnerships focusing on innovation and patient outcomes have gained traction.

Industry Experts Opinion

“Asleep DBS offers a safe, comfortable and less stressful experience for patients who are apprehensive about the surgery. Whether performed asleep or awake, DBS is proven to reduce motor symptoms in movement disorders like Parkinson’s.”

• Francisco Ponce, M.D., neurosurgeon and chief of stereotactic and functional neurosurgery at The Barrow Neurological Institute.

“The ability to see the precise placement of DBS Systems enables us to target therapy to meet individual needs. The new features in the Vercise Neural Navigator 5 are expected to help further reduce the time needed to adjust stimulation and minimize potential side effects, allowing us to optimize treatment benefits for each patient.”

• Mustafa Saad Siddiqui, M.D., professor of Neurology and Neurosurgery at Wake Forest School of Medicine and medical director of the DBS program at Atrium Health Wake Forest Baptist.

Segment Analysis

Based on the product type, the Deep Brain Stimulators (DBS) Markt is classified into Devices and Accessories. Devices dominate the Deep Brain Stimulators (DBS) market, with critical therapeutic applications in illnesses such as Parkinson's disease, essential tremor, and dystonia. These devices provide precise electrical stimulation to specific areas of the brain, allowing patients to alleviate symptoms and enhance their overall quality of life. This segment is benefiting from the growing use of DBS systems as a consequence of technological advancements, including enhancements to the DBS systems to make them safer, smaller, and less invasive. The rising occurrence of neurological disorders leads to the device segment's violent dominance in the global market as healthcare practitioners seek new ways to manage patients.

Based on the application, the Deep Brain Stimulators (DBS) Markt is classified into Parkinson’s Disease, Epilepsy, Essential Tremor, Dystonia, Obsessive-Compulsive Disorder (OCD), Other Neurological Disorders. Parkinson's disease is dominant in the application segment of the Deep Brain Stimulators (DBS) market. Parkinson's disease, a degenerative neuromuscular disorder characterized by tremor, rigidity, and geriatric movement impairment, has been significantly alleviated with DBS, hence increasing patients' quality of life. DBS has grown in popularity owing to its ability to improve motor control in people with Parkinson's disease while avoiding levodopa rolloff and L-dopa-related issues. The growing number of elderly people and the prevalence of Parkinson's disease are driving the growth of this market, which is regarded as a critical area of interest for companies developing neuromodulation drugs.

Regional Analysis

The deep brain stimulators (DBS) market in North America is continuously growing due to the increasing prevalence of neurological illnesses such as Parkinson's disease, essential tremor, and dystonia. Deep brain stimulation next-generation devices provide new programming capabilities and longer battery life, increasing the treatment's impact and patient adherence. Industry players, a well-developed healthcare structure, and increased investment in neurostimulation goods and research all help to support the industry. Furthermore, the increasing rate of understanding of the application of DBS as a therapeutic procedure by doctors and patients plays a role in the increase in its use. Similarly, regulatory frameworks and mutual reimbursement policies are significant drivers for DBS market expansion, with North America leading the worldwide DBS market.

The Asia Pacific DBS market is rapidly expanding due to increased rates of neurological illnesses such as Parkinson's disease, epilepsy, and depression. This is because DBS-related technologies, like gadget downsizing and long-life batteries, are gaining popularity. Furthermore, rising healthcare expenditures and growing awareness of surgery as a treatment option are driving the market. Countries such as Japan, China, and Australia have risen to the forefront owing to research funding and an increase in the number of qualified healthcare staff. Nevertheless, factors like high costs, lack of government support, and many regulatory procedures combined with different reimbursement policies can affect market development. Overall, the region is dynamic, offering chances to stakeholders in the DBS arena.

Competitive Landscape

The strategic context for the DBS market is highly competitive due to innovation and strategic cooperation between competitors, such as Medtronic, Boston Scientific, and Abbott Laboratories. Medtronic has marketed the latest DBS systems for the treatment of Parkinson’s disease and has come up with enhanced models as part of its programming capabilities. Boston Scientific is also advancing the FDA-approved company’s second-generation DBS system that enables better outcomes for patients via the delivery of adaptive stimulation. Abbott is diversifying at the moment by incorporating neuromodulation devices to address different neurological conditions. Further, NeuroPace and Synchron, among other companies, are developing responsive neurostimulation solutions that adjust to the patient's therapy demands as determined by biometrics. Emphasis on research and development along with strategic partnerships is fueling growth and improving the DBS therapy outcomes in multiple patient categories.

Deep Brain Stimulators (DBS) Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In August 2024, Medtronic received landmark FDA approval for its Asleep Deep Brain Stimulation surgery. This innovative approach allowed patients to undergo the procedure while under general anesthesia, making it more comfortable and less stressful. The approval marked a significant advancement in the treatment options available for neurological disorders.
• In July 2023, Boston Scientific received FDA approval for its advanced image-guided programming software for Deep Brain Stimulation. This new innovation enhanced the ability of clinicians to customize treatments more effectively by integrating advanced imaging techniques. The approval represented a significant step forward in optimizing patient outcomes in neurological therapies.

Report Coverage:

By Product Type

• Devices
  • Single-lead DBS systems
  • Dual-lead DBS systems
• Accessories
  • Batteries
  • Connectors
  • Leads

By Application

• Parkinson’s Disease
• Epilepsy
• Essential Tremor
• Dystonia
• Obsessive-Compulsive Disorder (OCD)
• Other Neurological Disorders

By Technology

• Conventional DBS Systems
• Responsive DBS Systems

By End User

• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centers
• Research Institutions

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic
• Boston Scientific
• Abbott Laboratories
• Neuropace
• St. Jude Medical
• Zynex Medical
• Bioness
• Inspire Medical Systems
• Medtronic’s Spinal and Biologics
• Nuvectra
• NeuroPace
• Elekta
• Civitas Therapeutics
• SentreHEART
• Synchron

Frequently Asked Questions (FAQs)